Mylan Stock Price, News & Analysis (NASDAQ:MYL)

$41.45 +0.17 (+0.41 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$41.28
Today's Range$41.16 - $42.00
52-Week Range$29.39 - $47.82
Volume3.37 million shs
Average Volume5.76 million shs
Market Capitalization$22.14 billion
P/E Ratio24.97
Dividend YieldN/A
Beta1.35

About Mylan (NASDAQ:MYL)

Mylan logoMylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.

Receive MYL News and Ratings via Email

Sign-up to receive the latest news and ratings for MYL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drugs - Generic
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:MYL
CUSIP62853010
Phone44-0-17-0785-3000

Debt

Debt-to-Equity Ratio1.05%
Current Ratio1.46%
Quick Ratio0.95%

Price-To-Earnings

Trailing P/E Ratio24.9698795180723
Forward P/E Ratio9.13
P/E Growth1.11

Sales & Book Value

Annual Sales$11.08 billion
Price / Sales2.01
Cash Flow$7.65 per share
Price / Cash5.42
Book Value$20.78 per share
Price / Book1.99

Profitability

Trailing EPS$1.66
Net Income$480 million
Net Margins7.28%
Return on Equity20.63%
Return on Assets7.19%

Miscellaneous

Employees35,000
Outstanding Shares536,440,000

Mylan (NASDAQ:MYL) Frequently Asked Questions

What is Mylan's stock symbol?

Mylan trades on the NASDAQ under the ticker symbol "MYL."

How were Mylan's earnings last quarter?

Mylan (NASDAQ:MYL) released its quarterly earnings data on Monday, November, 6th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $1.20 by $0.10. The company had revenue of $2.99 billion for the quarter, compared to analyst estimates of $3.09 billion. Mylan had a net margin of 7.28% and a return on equity of 20.63%. The company's revenue for the quarter was down 2.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.38 EPS. View Mylan's Earnings History.

When will Mylan make its next earnings announcement?

Mylan is scheduled to release their next quarterly earnings announcement on Wednesday, February, 28th 2018. View Earnings Estimates for Mylan.

Where is Mylan's stock going? Where will Mylan's stock price be in 2018?

18 analysts have issued 12 month target prices for Mylan's stock. Their forecasts range from $29.39 to $59.00. On average, they anticipate Mylan's share price to reach $45.02 in the next twelve months. View Analyst Ratings for Mylan.

What are Wall Street analysts saying about Mylan stock?

Here are some recent quotes from research analysts about Mylan stock:

  • 1. According to Zacks Investment Research, "Mylan received a major boost with the FDA approval for a generic version of Copaxone 40mg. The company being one of the first filers, will also enjoy 180 days of exclusivity. The FDA approval of biosimilar version of Herceptin will also boost the biosimilars portfolio. However, Mylan’s performance in 2017 was impacted by ongoing challenges in North America. The third quarter experienced an accelerated decline in EpiPen sales due to the launch of an authorized generic as well as the contraction of the overall epinephrine auto-injector market. Sales are expected to decline further. Moreover, the complete response letter from the FDA regarding its abbreviated new drug application ANDA for the generic version of asthma drug Advair Diskus was a setback given the market potential. Shares have performed better than the industry in the last one year." (1/16/2018)
  • 2. Cantor Fitzgerald analysts commented, "News outlets today reported State attorney generals are seeking to sue Mylan’s president and executive director, Rajiv Malik, as part of a civil investigation, according to Connecticut Attorney General George Jepsen." (10/31/2017)
  • 3. Argus analysts commented, "junior version" (8/22/2017)
  • 4. Mizuho analysts commented, "We were previously modeling 2017 generic Advair sales of $150M ramping to peak sales of $363M in 2020. Without the 2017 contribution we would still fall generally in line with consensus revenue estimates for 2017 (~$12.7B), which is below the mid-point of the guidance range of $12.25-13.75B. It is unclear if Mylan can get its product to the market before year end so it may be more conservative to exclude it for now, though we continue to anticipate its launch next year. While the limited visibility provided on this product may be frustrating to investors, we think that the magnitude of the stock reaction creates a buying opportunity given the small overall contribution from this generic in the near-term. We therefore reiterate our Buy rating and $53 PT. Next Advair-related event: Hikma/Vectura has a May 10 GDUFA date for their own generic Advair, and Hikma indicated that it will be ready to launch immediately after approval. Unlike Mylan’s product, which is hoped to be an AB-rated generic, but also one with brand recognition, Hikma’s generic will not be marketed under a brand name. Hikma mgmt has indicated that its Advair generic will make up the majority of its $120M new-launch guidance in 2017 (assuming one other competitor in the market)." (3/30/2017)
  • 5. Royal Bank of Canada analysts commented, "MYL reported 4Q today and hosted what we thought was an upbeat 2017 Investor Day showcasing an impressive pipeline. While overall performance remains stable avoiding headwinds felt by smaller peers, 2017 EPS and stock upside will be linked to a few key approvals along with business development. No change to Sector Perform rating but our price target moves up to $48 on higher EPS...First time 2017 guidance was favorable but there are a lot of moving parts to consider. We said going in that an ambitious 2017 outlook wouldn't be enough unless it came with a solid 4Q result. While visibility into specific 4Q drivers was not as high as we would like, it did provide some comfort around MYL's overall stability in a challenging generic environment. The 2017 guidance range of $5.15 to $5.55 captured consensus and helped drive the +7% move in the stock today, but focus will now shift to several important drivers to get there. As we suspected, that range includes risk-adjusted generic Advair, generic Copaxone 20/40mg as well as some incremental business development. Epipen profit impact was quantified and the driver of the slight gross margin moderation. Our new forecasts for 2017-19E move higher and are now $5.30, $5.75 and $6.12 (the $6.00 MYL EPS target in 2018E remains). Based on our new 2018 EBITDA, MYL trades at 9.1x EV/EBITDA - above historical pre-2014 levels." (3/2/2017)

Are investors shorting Mylan?

Mylan saw a drop in short interest in January. As of January 31st, there was short interest totalling 19,118,671 shares, a drop of 17.4% from the January 12th total of 23,140,267 shares. Based on an average daily trading volume, of 5,968,846 shares, the short-interest ratio is presently 3.2 days. Currently, 3.8% of the shares of the stock are short sold.

Who are some of Mylan's key competitors?

Who owns Mylan stock?

Mylan's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.56%), Pzena Investment Management LLC (4.10%), Geode Capital Management LLC (1.13%), Bank of New York Mellon Corp (0.99%), Franklin Resources Inc. (0.89%) and TIAA CREF Investment Management LLC (0.87%). Company insiders that own Mylan stock include Anthony Mauro, Heather M Bresch, Joseph C Md Maroon, Laboratories Abbott, Mark W Parrish, Melina E Higgins, Rajiv Malik, Robert J Cindrich, Robert J Coury and Wendy Cameron. View Institutional Ownership Trends for Mylan.

Who sold Mylan stock? Who is selling Mylan stock?

Mylan's stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., OppenheimerFunds Inc., Clal Insurance Enterprises Holdings Ltd, Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, Pzena Investment Management LLC, Schroder Investment Management Group, Ascend Capital LLC and BlackRock Inc.. Company insiders that have sold Mylan company stock in the last year include Anthony Mauro, Heather M Bresch, Laboratories Abbott and Rajiv Malik. View Insider Buying and Selling for Mylan.

Who bought Mylan stock? Who is buying Mylan stock?

Mylan's stock was purchased by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd., Millennium Management LLC, Bank of New York Mellon Corp, Clearbridge Investments LLC, Wells Fargo & Company MN, Jennison Associates LLC, Meitav Dash Investments Ltd. and Senzar Asset Management LLC. Company insiders that have bought Mylan stock in the last two years include Joseph C Md Maroon, Mark W Parrish, Melina E Higgins, Robert J Cindrich and Wendy Cameron. View Insider Buying and Selling for Mylan.

How do I buy Mylan stock?

Shares of Mylan can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mylan's stock price today?

One share of Mylan stock can currently be purchased for approximately $41.45.

How big of a company is Mylan?

Mylan has a market capitalization of $22.14 billion and generates $11.08 billion in revenue each year. The company earns $480 million in net income (profit) each year or $1.66 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

How can I contact Mylan?

Mylan's mailing address is BUILDING 4 TRIDENT PLACE MOSQUITO WAY, HATFIELD X0, AL10 9UL. The company can be reached via phone at 44-0-17-0785-3000.


MarketBeat Community Rating for Mylan (MYL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  582 (Vote Outperform)
Underperform Votes:  415 (Vote Underperform)
Total Votes:  997
MarketBeat's community ratings are surveys of what our community members think about Mylan and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Mylan (NASDAQ:MYL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.612.592.592.67
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $45.02$44.14$40.96$43.27
Price Target Upside: 8.10% upside5.78% downside9.55% upside42.16% upside

Mylan (NASDAQ:MYL) Consensus Price Target History

Price Target History for Mylan (NASDAQ:MYL)

Mylan (NASDAQ:MYL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2018JPMorgan Chase & Co.Set Price TargetBuy$53.00LowView Rating Details
1/25/2018Susquehanna BancsharesReiterated RatingPositive -> Positive$47.00 -> $55.00LowView Rating Details
1/24/2018Deutsche BankSet Price TargetBuy$50.00LowView Rating Details
1/18/2018Wells Fargo & CoSet Price TargetHold$33.00 -> $43.00LowView Rating Details
1/11/2018Goldman Sachs GroupBoost Price TargetBuy$46.00 -> $52.00HighView Rating Details
1/4/2018CitigroupReiterated RatingBuy -> Buy$48.00 -> $58.00HighView Rating Details
1/2/2018Leerink SwannInitiated CoverageMkt Perform -> Market Perform$44.00LowView Rating Details
12/26/2017Cantor FitzgeraldSet Price TargetHold$41.00LowView Rating Details
12/12/2017GuggenheimInitiated CoverageBuy -> Buy$59.00LowView Rating Details
11/7/2017Royal Bank of CanadaBoost Price TargetSector Perform -> Sector Perform$32.00 -> $37.00N/AView Rating Details
10/24/2017MizuhoReiterated RatingBuy$37.00N/AView Rating Details
10/6/2017Morgan StanleyBoost Price TargetEqual Weight$36.00 -> $39.00N/AView Rating Details
10/5/2017InstinetReiterated RatingBuy$37.00N/AView Rating Details
10/5/2017CowenReiterated RatingMarket Perform$30.00 -> $36.00N/AView Rating Details
10/4/2017BTIG ResearchBoost Price TargetBuy -> Buy$42.00 -> $45.00HighView Rating Details
9/29/2017BMO Capital MarketsReiterated RatingBuy$45.00LowView Rating Details
8/22/2017ArgusDowngradeBuy -> Hold$47.59 -> $29.39LowView Rating Details
5/22/2017BarclaysUpgradeEqual Weight -> Overweight$47.00 -> $50.00LowView Rating Details
12/30/2016Stifel NicolausReiterated RatingPositiveN/AView Rating Details
10/10/2016Raymond James FinancialUpgradeMarket Perform -> Strong-Buy$57.00N/AView Rating Details
9/23/2016Sanford C. BernsteinSet Price TargetBuy$60.00N/AView Rating Details
8/26/2016Evercore ISIReiterated RatingHold$49.00N/AView Rating Details
8/24/2016Bank of AmericaReiterated RatingBuy$70.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Mylan (NASDAQ:MYL) Earnings History and Estimates Chart

Earnings by Quarter for Mylan (NASDAQ:MYL)

Mylan (NASDAQ MYL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2018$1.42N/AView Earnings Details
11/6/2017Q3 2017$1.20$1.10$3.09 billion$2.99 billionViewN/AView Earnings Details
8/9/2017Q2 2017$1.18$1.10$3.00 billion$2.96 billionViewListenView Earnings Details
5/10/2017Q1 17$0.92$0.93$2.81 billion$2.72 billionViewN/AView Earnings Details
3/1/2017Q4 2016$1.42$1.57$3.18 billion$3.27 billionViewN/AView Earnings Details
11/9/2016Q3 2016$1.50$1.38$3.12 billion$3.06 billionViewListenView Earnings Details
8/9/2016Q216$1.13$1.16$2.58 billion$2.56 billionViewN/AView Earnings Details
5/3/2016Q116$0.74$0.76$2.23 billion$2.19 billionViewN/AView Earnings Details
2/10/2016Q415$1.27$1.22$2.71 billion$2.49 billionViewListenView Earnings Details
10/30/2015Q315$1.38$1.43$2.79 billion$2.71 billionViewListenView Earnings Details
8/6/2015Q215$0.89$0.91$2.39 billion$2.37 millionViewN/AView Earnings Details
5/5/2015Q115$0.70$0.70$2.22 billion$1.87 billionViewListenView Earnings Details
3/2/2015Q414$1.05$1.05$2.07 billion$2.08 billionViewListenView Earnings Details
10/30/2014Q314$1.14$1.16$2.06 billion$2.08 billionViewN/AView Earnings Details
8/7/2014Q214$0.70$0.69$1.88 billion$1.84 billionViewN/AView Earnings Details
5/1/2014Q114$0.63$0.66$1.80 billion$1.72 billionViewN/AView Earnings Details
2/27/2014Q413$0.75$0.78$1.81 billion$1.81 billionViewN/AView Earnings Details
10/31/2013Q313$0.79$0.82$1.84 billion$1.77 billionViewN/AView Earnings Details
8/1/2013Q2 2013$0.67$0.68$1.73 billion$1.70 billionViewN/AView Earnings Details
5/2/2013Q1 2013$0.62$0.62$1.69 billion$1.63 billionViewN/AView Earnings Details
2/27/2013Q4 2012$0.64$0.65$1.73 billion$1.72 billionViewN/AView Earnings Details
10/25/2012$0.77$0.83ViewN/AView Earnings Details
7/26/2012$0.55$0.60ViewN/AView Earnings Details
4/26/2012$0.51$0.52ViewN/AView Earnings Details
2/21/2012$0.50$0.53ViewN/AView Earnings Details
10/26/2011$0.51$0.55ViewN/AView Earnings Details
7/27/2011$0.45$0.52ViewN/AView Earnings Details
5/3/2011$0.44$0.44ViewN/AView Earnings Details
2/24/2011$0.45$0.45ViewN/AView Earnings Details
10/26/2010Q3 2010$0.42$0.43ViewN/AView Earnings Details
7/28/2010Q2 2010$0.38$0.37ViewN/AView Earnings Details
4/29/2010Q1 2010$0.34$0.36ViewN/AView Earnings Details
2/25/2010Q4 2009$0.30$0.33ViewN/AView Earnings Details
10/29/2009Q3 2009$0.27$0.32ViewN/AView Earnings Details
7/30/2009Q2 2009$0.29$0.32ViewN/AView Earnings Details
4/30/2009Q1 2009$0.27$0.22ViewN/AView Earnings Details
2/19/2009Q4 2008$0.14$0.26ViewN/AView Earnings Details
10/30/2008Q3 2008$0.12$0.23ViewN/AView Earnings Details
8/6/2008Q2 2008$0.10$0.16ViewN/AView Earnings Details
5/8/2008Q1 2008$0.08$0.09ViewN/AView Earnings Details
2/27/2008Q4 2007($0.06)$0.11ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Mylan (NASDAQ:MYL) Earnings Estimates

2018 EPS Consensus Estimate: $5.40
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$1.10$1.10$1.10
Q2 20181$1.32$1.32$1.32
Q3 20181$1.42$1.42$1.42
Q4 20181$1.56$1.56$1.56
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Mylan (NASDAQ:MYL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Mylan (NASDAQ MYL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.69%
Institutional Ownership Percentage: 76.86%
Insider Trades by Quarter for Mylan (NASDAQ:MYL)
Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Mylan (NASDAQ MYL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/9/2018Heather M. BreschCEOSell75,000$45.00$3,375,000.00View SEC Filing  
6/9/2017Anthony MauroInsiderSell10,000$40.00$400,000.00140,653View SEC Filing  
6/9/2017Rajiv MalikPresidentSell25,000$40.00$1,000,000.00799,855View SEC Filing  
3/23/2017Laboratories AbbottMajor ShareholderSell44,000,000$41.60$1,830,400,000.00View SEC Filing  
8/9/2016Heather M BreschCEOSell100,200$50.00$5,010,000.00828,318View SEC Filing  
6/3/2016Joseph C Md MaroonDirectorBuy1,670$44.95$75,066.5022,036View SEC Filing  
5/25/2016Robert J CindrichDirectorBuy1,190$42.47$50,539.3013,384View SEC Filing  
5/12/2016Melina E HigginsDirectorBuy19,900$38.68$769,732.001,872View SEC Filing  
5/6/2016Melina E HigginsDirectorBuy100$38.69$3,869.001,872View SEC Filing  
4/28/2016Melina E HigginsDirectorBuy35,000$42.92$1,502,200.00View SEC Filing  
4/5/2016Robert J CouryChairmanSell217,755$45.96$10,008,019.801,334,306View SEC Filing  
3/31/2016Joseph C Md MaroonDirectorBuy4,337$46.36$201,063.3216,124View SEC Filing  
3/17/2016Mark W ParrishDirectorBuy1,705$44.00$75,020.0031,365View SEC Filing  
3/8/2016Wendy CameronDirectorBuy2,190$45.69$100,061.1066,677View SEC Filing  
3/3/2016Robert J CindrichDirectorBuy2,187$45.83$100,230.2110,322View SEC Filing  
12/17/2015John D. SheehanCFOSell34,579$55.03$1,902,882.37171,251View SEC Filing  
6/15/2015Melina E HigginsDirectorSell8,351$73.08$610,291.08View SEC Filing  
2/3/2015Anthony MauroInsiderSell13,255$53.15$704,503.25View SEC Filing  
2/3/2015Heather M BreschCEOSell411,996$53.15$21,897,587.40View SEC Filing  
2/3/2015Rajiv MalikPresidentSell285,394$53.15$15,168,691.10View SEC Filing  
2/3/2015Robert J CouryChairmanSell947,119$52.55$49,771,103.45View SEC Filing  
2/3/2015Rodney L PiattDirectorSell46,000$53.15$2,444,900.00View SEC Filing  
11/26/2014John D SheehanCFOSell19,475$57.50$1,119,812.50View SEC Filing  
11/25/2014Heather M BreschCEOSell100,000$55.80$5,580,000.00View SEC Filing  
11/25/2014Rajiv MalikPresidentSell120,000$55.78$6,693,600.00View SEC Filing  
11/25/2014Robert J CouryChairmanSell165,700$55.78$9,242,746.00View SEC Filing  
11/24/2014Heather M BreschCEOSell80,222$55.86$4,481,200.92View SEC Filing  
11/24/2014Rajiv MalikPresidentSell84,300$55.86$4,708,998.00View SEC Filing  
11/24/2014Robert J CouryChairmanSell105,800$55.88$5,912,104.00View SEC Filing  
11/7/2014Melina E HigginsDirectorBuy14,000$52.45$734,300.00View SEC Filing  
9/18/2014Neil F DimickDirectorSell5,432$48.26$262,148.32View SEC Filing  
6/19/2014Neil F DimickDirectorSell5,432$50.81$275,999.92View SEC Filing  
4/22/2014Rajiv MalikPresidentSell80,000$50.00$4,000,000.00289,117View SEC Filing  
4/14/2014Heather BreschCEOSell75,000$46.07$3,455,250.00293,418View SEC Filing  
3/20/2014Neil DimickDirectorSell5,813$53.08$308,554.0432,136View SEC Filing  
3/14/2014C ToddDirectorSell10,000$53.00$530,000.0023,389View SEC Filing  
3/6/2014Harry KormanCOOSell31,970$54.54$1,743,643.80133,373View SEC Filing  
3/3/2014Anthony MauroInsiderSell20,000$54.81$1,096,200.0025,473View SEC Filing  
3/3/2014Daniel Rizzo, Jr.CAOSell8,003$55.50$444,166.5082,296View SEC Filing  
3/3/2014Douglas LeechDirectorSell10,000$55.40$554,000.0036,271View SEC Filing  
1/2/2014Neil DimickDirectorSell5,813$43.15$250,830.9532,136View SEC Filing  
12/19/2013Rodney PiattDirectorSell10,000$41.84$418,400.0062,436View SEC Filing  
12/12/2013Daniel Rizzo, Jr.CAOSell70,683$42.04$2,971,513.3268,971View SEC Filing  
12/12/2013Melina HigginsDirectorBuy5,000$42.03$210,150.00View SEC Filing  
9/6/2013Heather M BreschCEOSell160,000$35.35$5,656,000.00View SEC Filing  
6/3/2013Neil F DimickDirectorSell19,994$30.51$610,016.94View SEC Filing  
11/27/2012Daniel C Rizzo JrCAOSell161,124$27.28$4,395,462.72View SEC Filing  
11/2/2012Douglas J LeechDirectorSell44,280$25.94$1,148,623.20View SEC Filing  
11/1/2012Anthony MauroInsiderSell12,301$25.79$317,242.79View SEC Filing  
10/5/2012Anthony MauroInsiderSell12,296$24.84$305,432.64View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Mylan (NASDAQ MYL) News Headlines

Source:
DateHeadline
 Brokerages Anticipate Mylan (MYL) Will Announce Quarterly Sales of $3.27 Billion Brokerages Anticipate Mylan (MYL) Will Announce Quarterly Sales of $3.27 Billion
www.americanbankingnews.com - February 23 at 2:32 PM
Will Mylan (MYL) Disappoint Investors This Earnings Season?Will Mylan (MYL) Disappoint Investors This Earnings Season?
finance.yahoo.com - February 22 at 5:16 PM
Mylan (MYL) Announces Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDAs PEPFAR ... - StreetInsider.comMylan (MYL) Announces Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDA's PEPFAR ... - StreetInsider.com
www.streetinsider.com - February 22 at 8:36 AM
Momenta's (MNTA) Earnings & Revenues Surpass Estimates in Q4Momenta's (MNTA) Earnings & Revenues Surpass Estimates in Q4
finance.yahoo.com - February 22 at 8:36 AM
 Analysts Anticipate Mylan (MYL) to Post $1.42 Earnings Per Share Analysts Anticipate Mylan (MYL) to Post $1.42 Earnings Per Share
www.americanbankingnews.com - February 21 at 3:16 AM
Mylan (MYL) Set to Announce Earnings on WednesdayMylan (MYL) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - February 21 at 2:22 AM
Mylan (MYL) Announces Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDAs PEPFAR ProgramMylan (MYL) Announces Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDA's PEPFAR Program
www.streetinsider.com - February 20 at 5:10 PM
FDA tentatively OKs Mylans HIV combo pillFDA tentatively OKs Mylan's HIV combo pill
seekingalpha.com - February 20 at 5:10 PM
BRIEF-Mylan Receives Tentative Approval For Combination HIV Treatment DTG/FTC/TAF Under FDAs Pepfar ProgramBRIEF-Mylan Receives Tentative Approval For Combination HIV Treatment DTG/FTC/TAF Under FDA's Pepfar Program
www.reuters.com - February 20 at 8:21 AM
Mylan Receives Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDAs PEPFAR ProgramMylan Receives Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDA's PEPFAR Program
finance.yahoo.com - February 20 at 8:21 AM
[$$] Big Stock Buys: Bluebird, Walgreens, Mallinckrodt[$$] Big Stock Buys: Bluebird, Walgreens, Mallinckrodt
finance.yahoo.com - February 20 at 8:21 AM
How Amazon Could Lose Its Healthcare Bid While Drug Distributor Stocks WinHow Amazon Could Lose Its Healthcare Bid While Drug Distributor Stocks Win
seekingalpha.com - February 19 at 5:07 PM
Should You Be Tempted To Sell Mylan NV. (NASDAQ:MYL) Because Of Its PE Ratio?Should You Be Tempted To Sell Mylan NV. (NASDAQ:MYL) Because Of Its PE Ratio?
finance.yahoo.com - February 19 at 5:07 PM
Opioid makers gave $10 million to drug advocacy groupsOpioid makers gave $10 million to drug advocacy groups
www.msn.com - February 19 at 8:36 AM
Mylan (MYL) Stock Rating Lowered by TheStreetMylan (MYL) Stock Rating Lowered by TheStreet
www.americanbankingnews.com - February 18 at 9:22 PM
JPMorgan Chase & Co. Analysts Give Mylan (MYL) a $53.00 Price TargetJPMorgan Chase & Co. Analysts Give Mylan (MYL) a $53.00 Price Target
www.americanbankingnews.com - February 16 at 9:18 PM
J&J (JNJ) Gets FDA Nod for New Prostate Cancer Treatment (Revised)J&J (JNJ) Gets FDA Nod for New Prostate Cancer Treatment (Revised)
www.zacks.com - February 16 at 5:13 PM
It’s Time to Add Teva Pharmaceutical Industries Ltd (ADR) Stock to Your WatchlistIt’s Time to Add Teva Pharmaceutical Industries Ltd (ADR) Stock to Your Watchlist
finance.yahoo.com - February 16 at 5:13 PM
Top Stocks Warren Buffett Is Buying NowTop Stocks Warren Buffett Is Buying Now
www.fool.com - February 15 at 5:16 PM
Teva Stock Falls as Novartis Brings Another Copaxone GenericTeva Stock Falls as Novartis Brings Another Copaxone Generic
finance.yahoo.com - February 14 at 3:30 PM
Senate report says patient advocacy groups get kickbacks from opioid manufacturers - CNNSenate report says patient advocacy groups get kickbacks from opioid manufacturers - CNN
www.cnn.com - February 14 at 7:11 AM
Generic Drugmakers to Dump as Teva's Woes Continue in 2018Generic Drugmakers to Dump as Teva's Woes Continue in 2018
finance.yahoo.com - February 14 at 7:11 AM
3 Top Healthcare Stocks to Buy in February3 Top Healthcare Stocks to Buy in February
finance.yahoo.com - February 11 at 7:16 AM
Heres What Teva Pharmaceuticals Saying About Its FutureHere's What Teva Pharmaceutical's Saying About Its Future
www.fool.com - February 10 at 3:30 PM
Here's What Teva Pharmaceutical's Saying About Its FutureHere's What Teva Pharmaceutical's Saying About Its Future
finance.yahoo.com - February 10 at 3:30 PM
Mylan (MYL) Sees Significant Decrease in Short InterestMylan (MYL) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - February 10 at 2:24 AM
Will Teva Pharmaceuticals Pain Be Mylans Gain?Will Teva Pharmaceutical's Pain Be Mylan's Gain?
www.fool.com - February 9 at 3:35 PM
Mylan to Release 2017 Fourth Quarter and Full Year Results and 2018 Guidance on Feb. 28, 2018 - PR Newswire (press release)Mylan to Release 2017 Fourth Quarter and Full Year Results and 2018 Guidance on Feb. 28, 2018 - PR Newswire (press release)
www.prnewswire.com - February 9 at 7:06 AM
Mylan to Release 2017 Fourth Quarter and Full Year Results and 2018 Guidance on Feb. 28, 2018Mylan to Release 2017 Fourth Quarter and Full Year Results and 2018 Guidance on Feb. 28, 2018
finance.yahoo.com - February 8 at 3:27 PM
Bristol Myers earnings power shares in the green among a sea of redBristol Myers earnings power shares in the green among a sea of red
finance.yahoo.com - February 8 at 6:52 AM
Global Transdermal Skin Patches Market 2017-2025: Major Players are Teva Pharmaceutical Industries, Mylan Pharmaceuticals Inc, 3M Company, Accrux & Access PharmaceuticalsGlobal Transdermal Skin Patches Market 2017-2025: Major Players are Teva Pharmaceutical Industries, Mylan Pharmaceuticals Inc, 3M Company, Accrux & Access Pharmaceuticals
www.prnewswire.com - February 6 at 11:34 AM
$3.28 Billion in Sales Expected for Mylan (MYL) This Quarter$3.28 Billion in Sales Expected for Mylan (MYL) This Quarter
www.americanbankingnews.com - February 6 at 10:40 AM
Mylan Becomes Oversold (MYL) - NasdaqMylan Becomes Oversold (MYL) - Nasdaq
www.nasdaq.com - February 6 at 6:52 AM
What's in the Cards for Teva (TEVA) This Earnings Season?What's in the Cards for Teva (TEVA) This Earnings Season?
finance.yahoo.com - February 5 at 3:26 PM
 Brokerages Expect Mylan (MYL) Will Announce Earnings of $1.42 Per Share Brokerages Expect Mylan (MYL) Will Announce Earnings of $1.42 Per Share
www.americanbankingnews.com - February 4 at 3:16 AM
Mylan (MYL) Given Consensus Rating of "Buy" by BrokeragesMylan (MYL) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 3 at 1:38 PM
Mylan (MYL) Stock Rating Lowered by BidaskClubMylan (MYL) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - February 3 at 11:58 AM
Mylan launches generic HIV/AIDS drug - Pittsburgh Business TimesMylan launches generic HIV/AIDS drug - Pittsburgh Business Times
www.bizjournals.com - February 2 at 6:55 AM
Mylan Expands Access to HIV/AIDS Medicines with Launch of First Generic Sustiva® TabletsMylan Expands Access to HIV/AIDS Medicines with Launch of First Generic Sustiva® Tablets
www.prnewswire.com - February 1 at 8:06 AM
Mylan (MYL) & Biocon Announce Positive CHMP Opinion for Semglee - StreetInsider.comMylan (MYL) & Biocon Announce Positive CHMP Opinion for Semglee - StreetInsider.com
www.streetinsider.com - January 30 at 3:27 PM
Mylan (MYL) and Theravance Biopharma (TBHP) Report FDA Acceptance of New Drug Application for Revefenacin ... - StreetInsider.comMylan (MYL) and Theravance Biopharma (TBHP) Report FDA Acceptance of New Drug Application for Revefenacin ... - StreetInsider.com
www.streetinsider.com - January 30 at 3:27 PM
BRIEF-Theravance, Mylan Announce FDA Acceptance Of Marketing Application For RevefenacinBRIEF-Theravance, Mylan Announce FDA Acceptance Of Marketing Application For Revefenacin
www.reuters.com - January 29 at 3:28 PM
Mylan (MYL) and Theravance Biopharma (TBHP) Report FDA Acceptance of New Drug Application for Revefenacin (TD-4208)Mylan (MYL) and Theravance Biopharma (TBHP) Report FDA Acceptance of New Drug Application for Revefenacin (TD-4208)
www.streetinsider.com - January 29 at 3:28 PM
Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary DiseaseTheravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
www.prnewswire.com - January 29 at 8:37 AM
Mylan and Biocon Receive Positive CHMP Opinion for Semglee™, Biosimilar Insulin GlargineMylan and Biocon Receive Positive CHMP Opinion for Semglee™, Biosimilar Insulin Glargine
finance.yahoo.com - January 29 at 7:10 AM
Q1 2018 EPS Estimates for Mylan (MYL) Increased by Leerink SwannQ1 2018 EPS Estimates for Mylan (MYL) Increased by Leerink Swann
www.americanbankingnews.com - January 29 at 2:16 AM
Mylan (MYL) Downgraded to Buy at BidaskClubMylan (MYL) Downgraded to Buy at BidaskClub
www.americanbankingnews.com - January 27 at 2:52 PM
Susquehanna Bancshares Reiterates "Positive" Rating for Mylan (MYL)Susquehanna Bancshares Reiterates "Positive" Rating for Mylan (MYL)
www.americanbankingnews.com - January 25 at 9:40 PM
Mylan (MYL) Given a $50.00 Price Target at Deutsche BankMylan (MYL) Given a $50.00 Price Target at Deutsche Bank
www.americanbankingnews.com - January 24 at 10:50 PM
Mylan (MYL) PT Raised to $50 at Deutsche Bank; Reiterates Buy - StreetInsider.comMylan (MYL) PT Raised to $50 at Deutsche Bank; Reiterates Buy - StreetInsider.com
www.streetinsider.com - January 24 at 3:31 PM

SEC Filings

Mylan (NASDAQ:MYL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Mylan (NASDAQ:MYL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Mylan (NASDAQ MYL) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.